KPV

KPV is a tripeptide of lysine, proline and valine corresponding to the C-terminal 11-13 sequence of alpha-melanocyte-stimulating hormone. It is supplied as a lyophilised powder. Because the sequence is short, identity confirmation by mass spectrometry is straightforward and purity by reversed-phase HPLC is well resolved; short peptides also carry a higher relative risk of residual synthesis by-products, which is why the certificate of analysis and its stated method matter more, not less, for material of this class. Analytical values on this record are transcribed from supplier documentation.

The fragment emerged from structure-activity work on alpha-MSH in the 1980s and 1990s, which sought the minimal sequence retaining the anti-inflammatory behaviour observed for the parent hormone in experimental systems. KPV was identified as a fragment that retained measurable activity in several assays while lacking the pigmentary activity associated with the full hormone. Research interest has remained largely in mucosal and dermal inflammation models.

Reported mechanisms centre on modulation of NF-kB signalling in cultured epithelial and immune cells, reductions in pro-inflammatory cytokine output in stimulated cell systems, and transport into cells via the peptide transporters PepT1 and PepT2 in intestinal and colonic models. Animal work has used chemically induced colitis models to examine mucosal inflammation endpoints. Some studies report antimicrobial behaviour in culture against fungal and bacterial species. Each of these is an assay-level observation in a defined system.

PepT1-mediated uptake in intestinal epithelial models is reasonably well supported and has been examined by more than one group. Reduction of NF-kB-driven cytokine readouts in stimulated epithelial culture is a consistent in vitro finding. The absence of pigmentary activity relative to the parent hormone is well established. As a three-residue peptide it is analytically simple and inexpensive to verify, which makes documentation failures harder to excuse.

There are no completed randomised controlled human trials. The entire in vivo record is rodent, dominated by chemically induced colitis models that reproduce some but not all features of human inflammatory disease. Group sizes are small, and several of the most-cited findings rest on single studies from the same research programme without independent replication. Pharmacokinetic characterisation is minimal; the plasma half-life of an unmodified tripeptide is expected to be very short, and few papers address this directly. Antimicrobial reports are in vitro and use concentrations whose relevance to any intact system has not been established. The literature base here is genuinely thin, and a shorter honest record is the correct representation of it.

Store the lyophilised solid as stated on this record, protected from light and moisture, and allow the sealed vial to reach ambient temperature before opening. Short peptides are hygroscopic and degrade fastest under humidity and repeated temperature cycling. This section concerns laboratory handling of the material as supplied and provides no preparation or administration procedure.

Indexed citations with verified PMIDs are listed below. Analytical methods behind the specification are described in testing methodology, documentation requirements in sourcing standards, and related records in the compound index.